CA
MBVX

Centerpoint Advisors’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Centerpoint Advisors’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-203
Closed – – 388
2018
Q2 		$0 Hold
203
– – ﹤0.01% 412
2018
Q1 		$0 Hold
203
– – ﹤0.01% 265
2017
Q4 		$0 Buy
+203
New +$449 ﹤0.01% 206

Other funds holding MBVX

PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Centerpoint Advisors's MBVX Position: Q3 2018 in Review

Centerpoint Advisors sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q3 2018, closing a stake of 203 shares.

Centerpoint Advisors first reported a position in MBVX in Q4 2017 and held it in 3 quarters. The position peaked at $0 in Q2 2018. 2 funds tracked by Wall St. Rank hold MBVX as of Q3 2018.

  • Centerpoint Advisors reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q3 2018 after selling out during the quarter.
  • Centerpoint Advisors sold 203 MABVAX THERAPEUTICS HLDGS INC shares in Q3 2018.
  • Centerpoint Advisors first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q4 2017 and held it in 3 quarters.
  • Centerpoint Advisors's MABVAX THERAPEUTICS HLDGS INC position peaked at $0 in Q2 2018.
  • 2 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q3 2018.

Based on Centerpoint Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.